Charles Foster
Ophthalmology · Waltham, MANPI 1285617530
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $15,900 of the $23,916 with a category attached, or 66.5%. 25 manufacturers reported payments, led by Bausch & Lomb Americas Inc. at 56.7% of the total. 2025 is the largest year on record at $7,639, 7.5 times the $1,014 reported in 2019. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 239 payments — averaging $100.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$14K
- Dompe US, Inc.$2K
- Mallinckrodt Hospital Products Inc.$2K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$2K
- AbbVie$1K
- Sun Pharmaceutical Industries Inc.$489
- plus $2K from 19 others
Across 67 payments — averaging $12,900 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Mallinckrodt Hospital Products Inc.$576K
- Eyepoint US, Inc.$155K
- Mallinckrodt Enterprises LLC$113K
- Bausch Health US, LLC$16K
- AbbVie$5K
What the payments were for
- Consulting fees$1,5006%
- Speaking & faculty fees$15,90066%
- Food & beverage$6,51627%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 5 | $13,570 |
| Dompe US, Inc. | 5 | $2,490 |
| Mallinckrodt Hospital Products Inc. | 55 | $1,916 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 17 | $1,838 |
| AbbVie(2 entities) | 46 | $1,171 |
| Sun Pharmaceutical Industries Inc. | 20 | $489 |
| Alimera Sciences, Inc. | 14 | $354 |
| Amgen | 10 | $288 |
| Eyepoint US, Inc. | 11 | $285 |
| Mallinckrodt Enterprises LLC | 4 | $250 |
| Oyster Point Pharma, Inc. | 8 | $225 |
| Novartis | 11 | $218 |
| Samsara Vision | 1 | $139 |
| Eyevance Pharmaceuticals LLC | 7 | $105 |
| ANI Pharmaceuticals, Inc. | 4 | $98 |
| Ocular Therapeutix, Inc. | 4 | $89 |
| Alcon | 3 | $71 |
| Genentech USA, Inc. | 3 | $65 |
| Aerie Pharmaceuticals, Inc. | 3 | $60 |
| Astellas Pharma US Inc | 2 | $56 |
| Vyera Pharmaceuticals, LLC | 2 | $44 |
| Coherus Oncology, Inc. | 1 | $29 |
| Shire North American Group Inc | 1 | $24 |
| Rayner Intraocular Lenses Limited | 1 | $20 |
| Apellis Pharmaceuticals, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,916 in reported general payments places this provider in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 32 | $288,862 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 13 | $236,206 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 14 | $143,732 |
| ProlensaBromfenac Sodium | 23 | $12,942 |
| LumiganBimatoprost | 20 | $9,845 |
| Bromfenac Sodium | 19 | $5,813 |
| Brimonidine Tartrate | 24 | $5,628 |
| Memantine Hcl ErMemantine Hcl | 14 | $1,847 |
| Prednisolone Acetate | 14 | $1,074 |
| MethotrexateMethotrexate Sodium | 15 | $634 |
| Celecoxib | 14 | $330 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 15 | $301 |
| Acyclovir | 15 | $191 |
| Doxycycline Hyclate | 15 | $183 |
| Naproxen | 13 | $173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $1,838 | $12,94223 claims |
| AbbVieLumigan | $1,171 | $9,84520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Waltham
- Peter ChangWaltham$992K
- Stephen AnesiWaltham$922K
- Jonathan TalamoWaltham$225K
- Nandini VenkateswaranWaltham$149K
- Rishi SinghBoston$1.7M
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.